Literature DB >> 11995920

Effect of activins AB and B on DNA synthesis stimulated by epidermal growth factor in primary cultured rat hepatocytes.

Shingo Niimi1, Mai Horikawa, Taiichiro Seki, Toyohiko Ariga, Tetsu Kobayashi, Takao Hayakawa.   

Abstract

The effect of activins AB and B on DNA synthesis stimulated by epidermal growth factor (EGF) was studied in primary cultured rat hepatocytes and compared with the effect of activin A, a suppressor of DNA synthesis. Activin AB inhibited DNA synthesis as assessed by [3H]thymidine incorporation. The inhibition by activin AB was detected at 6 ng/ml, and the 12.5 ng/ml concentration produced almost maximal inhibition, approximately 40%, almost the same as that produced by activin A. Inhibition by activin A was detected at 3 ng/ml, and the 6 ng/ml concentration produced almost maximal inhibition. Activin B, on the other hand, had no effect on DNA synthesis up to 50 ng/ml. The increase in labeling index by EGF was also reduced to about 20% by 25 ng/ml activin A and activin AB, but not by activin B. Activin B, however, inhibited the binding of [125I]activin A to hepatocytes, but had no effect on the inhibition of DNA synthesis by activin A, even at 3-fold excess concentrations. These findings suggest that activin AB may act in the same manner as activin A does in terms EGF's inhibitory effect on DNA synthesis, although the effective concentration is higher than that of activin A. The findings also suggest that activin B receptors are present in hepatocytes but that they do not mediate signal transduction leading to the inhibition of DNA synthesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11995920     DOI: 10.1248/bpb.25.437

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  7 in total

1.  Activins and follistatins: Emerging roles in liver physiology and cancer.

Authors:  Emanuel Kreidl; Deniz Oztürk; Thomas Metzner; Walter Berger; Michael Grusch
Journal:  World J Hepatol       Date:  2009-10-31

2.  Activin A, p15INK4b signaling, and cell competition promote stem/progenitor cell repopulation of livers in aging rats.

Authors:  Anuradha Menthena; Christoph I Koehler; Jaswinderpal S Sandhu; Mladen I Yovchev; Ethel Hurston; David A Shafritz; Michael Oertel
Journal:  Gastroenterology       Date:  2010-12-11       Impact factor: 22.682

Review 3.  Activins and activin antagonists in hepatocellular carcinoma.

Authors:  Alev Deli; Emanuel Kreidl; Stefan Santifaller; Barbara Trotter; Katja Seir; Walter Berger; Rolf Schulte-Hermann; Chantal Rodgarkia-Dara; Michael Grusch
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

4.  Inhibin/activin expression in human and rodent liver: subunits α and βB as new players in human hepatocellular carcinoma?

Authors:  K Frost; K Seir; A Lackner; M Grusch; B Grasl-Kraupp; R Schulte-Hermann; C Rodgarkia-Dara
Journal:  Br J Cancer       Date:  2011-03-15       Impact factor: 7.640

5.  Mir-34a is upregulated during liver regeneration in rats and is associated with the suppression of hepatocyte proliferation.

Authors:  Huan Chen; Yimin Sun; Ruiqi Dong; Shengsheng Yang; Chuanyong Pan; Dao Xiang; Mingyong Miao; Binghua Jiao
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

6.  Profiling Activins and Follistatin in Colorectal Cancer According to Clinical Stage, Tumour Sidedness and Smad4 Status.

Authors:  Bassem Refaat; Jamal Zekri; Akhmed Aslam; Jawwad Ahmad; Mohammed A Baghdadi; Abdelrazak Meliti; Shakir Idris; Sufian Sultan; Hosam Alardati; Haitham Akram Saimeh; Aiman Alsaegh; Mai Alhadrami; Tahira Hamid; Mohammed E Naeem; Shereef Ahmed Elsamany
Journal:  Pathol Oncol Res       Date:  2021-11-15       Impact factor: 3.201

7.  Activin B induces human endometrial cancer cell adhesion, migration and invasion by up-regulating integrin β3 via SMAD2/3 signaling.

Authors:  Siyuan Xiong; Christian Klausen; Jung-Chien Cheng; Hua Zhu; Peter C K Leung
Journal:  Oncotarget       Date:  2015-10-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.